Currently published studies have suggested a crucial role of TLRs/NF-κB signaling transduction in the development of some autoimmune diseases including RA, Sjogren's syndrome and systemic sclerosis [30–32], supporting multiple promising therapeutic targets for these diseases. This evidence concerns the gene NFKB1 and rheumatoid arthritis.